This letter describes the first demonstration of clinical response to the anti-EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide-spectrum mutational analyses.
Fiorentino M, Giunchi F, Altimari A, Di Tullio P, Gruppioni E, Martorana G, et al. (2014). Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations. THE ONCOLOGIST, 19(40), 430-430 [10.1634/theoncologist.2013-0346].
Learning From Errors: Response to Gefitinib in Kidney Urothelial Carcinoma With EGFR Mutations
FIORENTINO, MICHELANGELO;
2014
Abstract
This letter describes the first demonstration of clinical response to the anti-EGFR inhibitor gefitinib in a case of urothelial carcinoma of the renal pelvis harboring a rare EGFR double mutation. New mutations and unexpected clinical responses should be always explored through wide-spectrum mutational analyses.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
